3 / 6
Volume 10
Journal of Cancer Science & Therapy
Oncologists 2018
May 24-25, 2018
Page 14
Notes:
conference
series
.com
May 24-25, 2018 Osaka, Japan
22
nd
Global Annual Oncologists Meeting
Cellular senescence in Hodgkin’s lymphoma
H
odgkin’s Lymphoma (HL) is a B cell originated malignancy of the immune system. Although the rate of cure is high,
about 20-35% of patients relapse and about half of them eventually die of the disease or treatment-related late toxicities
and secondary malignancies. Conceptually novel treatment strategies are thus needed, particularly for this category of patients.
The malignant cells, called Hodgkin and Reed-Sternberg (HRS) cells, only make up 1-2% of the total tumor cellularity, the
remaining mass comprising a mixed infiltrate population is thought to be recruited to the lymph node by HRS-driven pro-
inflammatory signals. We propose that a sub-population of HRS cells, which we call herein large RS cells, have characteristics
of senescent cells, and, thus produce large amounts of inflammatory mediators (the so-called Senescence-Associated Secretory
Phenotype or SASP). Senescence is characterized by permanent cell cycle arrest and loss of proliferative capacity, despite
continued viability and metabolic activity. We show that the senescence markers the cell cycle inhibitors p16INK4a and
p21Cip1 are expressed in large RS cells in all HL biopsies examined. Moreover, the large RS cells are negative for Ki-67 staining,
demonstrating that these cells have ceased to proliferate. We also show that large, ‘RS-like’ cells in a HL-derived line, L428,
stained for the characteristic senescence marker β-galactosidase (β-gal). Oxidative stress and chemotherapy increased the
proportion of β-gal positive large RS cells. Furthermore, we show that the large RS cells secrete high levels of cytokines. We
suggest that these senescent RS cells may be responsible, at least in part, for creating a pro-inflammatory microenvironment,
promoting HL pathogenesis, and mediating chemoresistance in relapsed disease. Understanding the pathways important for
the establishment of senescence in HRS cells, as well gaining insight into targetable mechanisms for the eradication of these
cells, will provide new therapeutic approaches for HL patients with recurrent or chemo-resistant disease.
Biography
Jacob Gopas has completed his BSc from Bar-Ilan University, Israel, PhD from Albert Einstein College of Medicine, USA and Post-doctorate from Ben-Gurion
University. He is a Professor, Head of the Laboratory of the Institute of Oncology, Soroka University Medical Center, Israel and teaches cell and cancer biology.
His research includes basic and clinical cancer biology, Hodgkin’s lymphoma, and new plant compounds against inflammation, pathogens and cancer. He has
published more than 90 articles together with Israeli, German, Indian and American scientists and physicians and holds several patents (founded by the Israel
Science Foundation, Israel Ministry of Health, Israel Ministry of Science, Israel Cancer Association and NIH).
jacob@bgu.ac.ilJacob Gopas
Ben-Gurion University of the Negev, Israel
Soroka University Medical Center, Israel
Jacob Gopas, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C3-128